Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart Failure

[1]  L. Lazzeroni,et al.  An &agr;2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the &bgr;-Blocker Bucindolol in Chronic Heart Failure , 2010, Circulation. Heart failure.

[2]  S. Ball,et al.  Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF substudy. , 2009, Journal of cardiac failure.

[3]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[4]  W. Kraus,et al.  Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. , 2008, Journal of the American College of Cardiology.

[5]  D. Mann,et al.  Pharmacogenomics and the failing heart are we waiting for godot? , 2008, Journal of the American College of Cardiology.

[6]  S. Humphries,et al.  Role of β adrenergic receptor polymorphisms in heart failure: Systematic review and meta‐analysis , 2008, European journal of heart failure.

[7]  J. Atherton,et al.  Arg389Gly-&bgr;1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol , 2007, Pharmacogenetics and genomics.

[8]  N. Lamblin,et al.  The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. , 2007, American heart journal.

[9]  Julie A. Johnson,et al.  Synergistic polymorphisms of &bgr;1 and &agr;2C-adrenergic receptors and the influence on left ventricular ejection fraction response to &bgr;-blocker therapy in heart failure , 2007 .

[10]  I. Zineh,et al.  Relation of β2-Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure , 2007 .

[11]  L. Lazzeroni,et al.  A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure , 2006 .

[12]  M. Metra,et al.  Role of β1‐ and α2c‐adrenergic receptor polymorphisms and their combination in heart failure: A case‐control study , 2006 .

[13]  P. Amouyel,et al.  The impact of beta‐adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure * , 2005, European journal of heart failure.

[14]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[15]  M David Tilson,et al.  The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease. , 2005, Circulation.

[16]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[17]  Julie A. Johnson,et al.  Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. , 2005, Pharmacogenetics and genomics.

[18]  M. Metra,et al.  Role of β1- and β2-adrenoceptor polymorphisms in heart failure: a case-control study , 2004 .

[19]  D. Bello,et al.  Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 2004, The American journal of cardiology.

[20]  S. Liggett,et al.  Pharmacology and physiology of human adrenergic receptor polymorphisms. , 2003, Annual review of pharmacology and toxicology.

[21]  A. DeMaria,et al.  Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With &bgr;-Blockade in Patients With Heart Failure: The &bgr;-Blocker Evaluation of Survival Trial (BEST) , 2003, Circulation.

[22]  J. Cohn,et al.  Ventricular remodeling in heart failure: a credible surrogate endpoint. , 2003, Journal of cardiac failure.

[23]  G. Dorn,et al.  β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.

[24]  S. Ball,et al.  An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study , 2003, European journal of heart failure.

[25]  G. Jennings,et al.  Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. , 2003, Pharmacogenetics.

[26]  M. Metra,et al.  Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. , 2003, American heart journal.

[27]  G. Francis,et al.  Beta-blockers and reverse remodeling: what are the implications? , 2003, American heart journal.

[28]  P. Insel,et al.  The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. , 2003, Pharmacogenetics.

[29]  Julie A. Johnson,et al.  β-Adrenergic Receptor Polymorphisms: Cardiovascular Disease Associations and Pharmacogenetics , 2002, Pharmaceutical Research.

[30]  S. Kardia,et al.  Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure , 2002 .

[31]  R. Kim,et al.  The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. , 2001, The New England journal of medicine.

[32]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[33]  M. Metra,et al.  A rationale for the use of β-blockers as standard treatment for heart failure , 2000 .

[34]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[35]  D. A. Mason,et al.  A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.

[36]  M. Hetzel,et al.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). , 1997, Circulation.

[37]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[38]  M. Metra,et al.  Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.

[39]  S. Green,et al.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.

[40]  I. Zineh,et al.  Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. , 2007, The American journal of cardiology.

[41]  Julie A. Johnson,et al.  Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. , 2007, Pharmacogenetics and genomics.

[42]  M. Metra,et al.  Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. , 2006, European journal of heart failure.

[43]  H. Bruck,et al.  Cardiac adrenoceptors: physiological and pathophysiological relevance. , 2006, Journal of pharmacological sciences.

[44]  L. Lazzeroni,et al.  A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Metra,et al.  Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. , 2004, European heart journal.

[46]  M. Metra,et al.  A rationale for the use of beta-blockers as standard treatment for heart failure. , 2000, American heart journal.

[47]  M. Bristow.  beta-adrenergic receptor blockade in chronic heart failure. , 2000, Circulation.